12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Sarepta Therapeutics preclinical data

In non-human primates infected with Marburg virus, once-daily 7.5-30 mg/kg doses of intramuscular AVI-7288 given 1 hour post-infection and for 13 subsequent days produced 83-100% survival rates over a 40-day evaluation period vs. 0% for placebo. Last year, Sarepta reported that IV AVI-7288 given up to 4...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >